From Exhibit A of Exhibit 10.1 from the filing:
Post# of 30028
Posted On: 10/10/2014 4:32:51 PM
From Exhibit A of Exhibit 10.1 from the filing:
http://www.sec.gov/Archives/edgar/data/142481...ex10-1.htm
Milestone: Nasdaq uplist
Bonus Performance: 30%
Completion Timing: 12/31/14
Milestone: Eltoprazine US IND filed and approved for LID
Bonus Performance: 30%
Completion Timing: 12/31/14
Milestone: LymPro partner validation of analytical performance package (APP) and CLIA certification
Bonus Performance: 25%
Completion Timing: 12/31/14
Milestone: MANF Orphan drug designation applications filed and approved for both Ocular Ischemic Syndrome (OIA) and Retinitis Pigmentosa
Bonus Performance: 15%
Completion Timing: 12/31/14
http://www.sec.gov/Archives/edgar/data/142481...ex10-1.htm
Milestone: Nasdaq uplist
Bonus Performance: 30%
Completion Timing: 12/31/14
Milestone: Eltoprazine US IND filed and approved for LID
Bonus Performance: 30%
Completion Timing: 12/31/14
Milestone: LymPro partner validation of analytical performance package (APP) and CLIA certification
Bonus Performance: 25%
Completion Timing: 12/31/14
Milestone: MANF Orphan drug designation applications filed and approved for both Ocular Ischemic Syndrome (OIA) and Retinitis Pigmentosa
Bonus Performance: 15%
Completion Timing: 12/31/14
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼